Halozyme Therapeutics, Inc.

The US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a

Pfizer is pushing ahead with its effort to jump back into immune checkpoint inhibitor therapy with new Phase III results showing efficacy for its subcutaneous PD-1 inhibitor sasanlimab in non-muscle i

Bristol Myers Squibb’s Opdivo Qvantig, the new subcutaneous version of its PD-1 inhibitor Opdivo (nivolumab), will be available starting in early January with a list price that is at parity with the o

US Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan